AN OPEN-LABEL, RANDOMIZED, MULTICENTER STUDY EVALUATING THE ACTIVITY OF LASOFOXIFENE RELATIVE TO FULVESTRANT FOR THE TREATMENT OF PRE- AND POSTMENOPAUSAL WOMEN WITH LOCALLY ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER WITH AN ESR1 MUTATION

Registry ID

SMX 18-001

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

SERMONIX PHARMACEUTICALS INC.

Start date

2020-10-02

Last update

2020-05-27

Conditions

• ER+/HER2-BREAST CANCER
• BREAST CANCER METASTATIC

Related clinical trials

• A PHASE 3 RANDOMIZED, DOUBLE-BLIND, ACTIVE-CONTROLLED STUDY OF PALAZESTRANT WITH RIBOCICLIB VERSUS LETROZOLE WITH RIBOCICLIB FOR THE FIRST-LINE TREATMENT OF ER+, HER2–ADVANCED BREAST CANCER (OPERA-02)
• CAPECITABINE FOR TARGETED ERADICATION OF ARISING CTDNA MOLECULAR RESIDUAL DISEASE IN ER+/HER2- NEGATIVE BREAST CANCER
• HERTHENA-BREAST-01: A PHASE 1B/2, MULTICENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY AND ANTITUMOR ACTIVITY OF PATRITUMAB DERUXTECAN IN PARTICIPANTS WITH HER2 POSITIVE UNRESECTABLE LOCALLY ADVANCED BREAST CANCER OR METASTATIC BREAST CANCER
• A RANDOMIZED, OPEN-LABEL STUDY COMPARING THE BRIA-IMT REGIMEN IN COMBINATION WITH CHECK POINT INHIBITOR VS PHYSICIAN'S CHOICE IN METASTATIC BREAST CANCER
• A PHASE I/II, OPEN-LABEL, MULTI-CENTER TRIAL OF [177LU]LU-NEOB IN COMBINATION WITH CAPECITABINE IN ADULT PATIENTS WITH GRPR+, ER+, HER2- METASTATIC BREAST CANCER AFTER PROGRESSION ON PREVIOUS ENDOCRINE THERAPY IN COMBINATION WITH A CDK4/6 INHIBITOR.
• A PHASE 3, RANDOMIZED, MULTI-CENTER, OPEN-LABEL STUDY OF DB-1303 VERSUS INVESTIGATOR¿S CHOICE CHEMOTHERAPY IN HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-LOW, HORMONE RECEPTOR POSITIVE (HR+) METASTATIC BREAST CANCER PATIENTS WHOSE DISEASE HAS PROGRESSED ON ENDOCRINE THERAPY (ET) (DYNASTY-BREAST02)

View on source registry